参松养心胶囊联合胺碘酮治疗老年冠心病并室性期前收缩的疗效

Shensong Yangxin capsule combined with amiodarone on premature ventricular contraction in aged patients with coronary heart diseases

摘要:

目的 观察参松养心胶囊联合胺碘酮治疗老年冠心病并室性期前收缩的疗效。方法 选择2011年1月至2012年12月解放军第163医院冠心病伴室性期前收缩的老年患者68例，其中男性62例，女性6例，年龄67～80（74.6±3.9）岁。将68例患者随机分为试验组（34例）和对照组（34例）。对照组在原发病常规治疗基础上加用盐酸胺碘酮片口服；试验组在对照组治疗基础上加用参松养心胶囊口服，疗程均为4周。观察2组治疗前后的24h动态心电图、症状和不良反应。结果 治疗后试验组室性期前收缩改善显效9例，有效21例，无效4例，改善总有效率88.2%，对照组显效5例，有效20例，无效9例，改善总有效率73.5%，两组比较差异有统计学意义（P＜0.05）。试验组症状改善显效8例，有效21例，无效5例，总有效率85.3%，对照组症状改善显效4例，有效22例，无效8例，总有效率76.5%，两组比较差异有统计学意义（P＜0.05）。试验组与对照组不良反应均较少，不良反应发生率差异无统计学意义（5.9% vs 8.8%，P＞0.05）。结论 参松养心胶囊联合胺碘酮治疗老年冠心病并室性期前收缩的疗效优于单用胺碘酮的疗效，安全性较好。

Abstract:

Objective To determine the clinical efficacy of Shensong Yangxin capsule (a traditional Chinese medicine) combined with amiodarone in treatment of premature ventricular contraction (PVC) in aged patients with coronary heart diseases. Methods A total of 68 patients with coronary heart diseases complicated with PVC hospitalized from January 2011 to December 2012 were recruited in this study. There were 62 males and 6 females, with age ranging from 67 to 80 (74.6±3.9) years. The patients were randomly divided into experimental group and control group, with 34 cases in each group. Both groups were treated with conventional therapy, and the control group was given amiodarone for 4 weeks, while, the experimental group received Shensong Yangxin capsule combined with amiodarone for 4 weeks. The clinical efficacy and adverse reactions in the 2 groups before and at 24h after treatment were observed by 24-hour dynamic electrocardiogram monitoring and signs and symptoms. Results After treatment, PVC in the experimental group was improved in 9 cases, effective in 21 cases, and invalid in 4 cases, with a total effective rate of 88.2%. While for the control group, PVC was improved in 5 cases, effective in 20 cases, and invalid in 9 cases, and the total effective rate was 73.5%. The total effective rate was significantly higher in the experimental group than in the control group (P＜0.05). After treatment, the symptoms in the experimental group was improved in 8 cases, effective in 21 cases, and invalid in 5 cases, and the total effective rate was 85.3%. While, the symptoms of the control group was improved in 4 cases, effective in 22 cases, and invalid in 8 cases, and the total effective rate was 76.5%. There was significant difference in the total effective rate between the 2 groups (P＜0.05). There were few adverse reactions found in the 2 groups, which was no significant difference between them (5.9% vs 8.8%, P＞0.05). Conclusion Shensong Yangxin capsule combined with amiodarone is safe and more effective than amiodarone alone in the treatment of PVC in aged patients with coronary heart diseases.